April 28, 2022 Download PDF PITTSBURGH, April 28, 2022 (GLOBE NEWSWIRE) --  Jeune Aesthetics, Inc. (“Jeune Aesthetics”), a wholly-owned subsidiary of  Krystal Biotech, Inc.  (“Krystal”) (NASDAQ: KRYS) today announced the formation and members of its Scientific Advisory Board, comprised of industry

PITTSBURGH , April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with dystrophic epidermolysis bullosa (DEB), who are enrolled in the GEM-3 open label extension study, the

Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in patients with recessive dystrophic epidermolysis bullosa (RDEB) compared with placebo with minimal

PITTSBURGH , March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . , (“ Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results from the GEM-3 Phase 3 study of beremagene geperpavec (B-VEC), an investigational, topical gene

PITTSBURGH , March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan , Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and

Positive proof-of-concept efficacy data supports advancing into Phase 2 studies Adverse events, associated with injection site reactions, were mild and transitory Conference call to discuss results scheduled for Tuesday, March 22, 2022 at 8:00 a.m. ET PITTSBURGH, March 22, 2022 (GLOBE NEWSWIRE) --

PITTSBURGH , March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present late-breaking research at the 2022 American Academy of Dermatology Annual Meeting, taking place March

PITTSBURGH , March 15, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it has reached a binding term sheet with PeriphaGen, Inc. (“PeriphaGen”) to resolve all claims in the trade secret litigation

Following successful completion of GEM-3 pivotal trial, Krystal is on track to file BLA for Vyjuvek™ for the treatment of dystrophic epidermolysis bullosa in 1H 2022; MAA filing anticipated in 2H 2022 Phase 1 trial of KB407 in cystic fibrosis patients in Australia expected to begin in 1H 2022; IND

PITTSBURGH , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference,